Amino.Desk

Larazotide

Updated Nov 17, 2026 · Clinical review: pending

Larazotide is an oral peptide that was tested as an add-on to the gluten-free diet in celiac disease. It is now sold as a "leaky gut" peptide and added to some blends. Its Phase 3 trial was stopped in 2022 because the interim results showed it was unlikely to succeed.

What it is

Larazotide acetate, also called AT-1001, is a chain of eight amino acids. It was designed to tighten the junctions between the cells that line the gut, so that less gluten slips through. It was the first celiac drug candidate to reach Phase 3.

What the evidence shows

No trial has tested it for the general gut, skin or inflammation claims it is sold for.

Legal status

Reported dosing

No dose has been established.

Development ended before an approved dose was set, and the positive Phase 2 result was at a single dose level that the larger trial did not confirm. The trials used capsules. No trial has tested it by injection, which is how blends deliver it.

Safety

Common questions

Is larazotide approved for celiac disease?

No. Its Phase 3 trial was stopped in 2022 and it is not FDA-approved for anything.

Why was the larazotide trial stopped?

An interim analysis found no statistically significant benefit, and continuing would have needed far more patients than was feasible.

Does larazotide fix leaky gut?

No trial has tested that claim outside celiac disease.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy